Literature DB >> 31014099

Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes Trial.

Jin J Zhou1,2, Juraj Koska2, Gideon Bahn3, Peter Reaven2.   

Abstract

Diabetes is associated with substantially increased mortality. Classic risk factors explain a portion of the excess of mortality in type 2 diabetes. The aim of this study was to examine whether visit-to-visit variation in fasting glucose and haemoglobin A1c values in the Veteran Affairs Diabetes Trial were associated with all-cause mortality in patients with type 2 diabetes in addition to other comorbidity conditions, hypoglycaemic events and adverse lifestyle behaviours. The Veteran Affairs Diabetes Trial was a randomized trial that enrolled 1791 military veterans who had a suboptimal response to therapy for type 2 diabetes to receive either intensive or standard glucose control. During the Veteran Affairs Diabetes Trial, fasting glucose and haemoglobin A1c were measured quarterly for up to 84 months. Variability measures included coefficient of variation and average real variability. We found that variability measures (coefficient of variation and average real variability) of fasting glucose were predictors of all-cause mortality, even after adjusting for comorbidity index, mean fasting glucose and adverse lifestyle behaviour during the study. Accounting for severe hypoglycaemia did not weaken this association. Our analysis indicates that in the Veteran Affairs Diabetes Trial, longitudinal variation in fasting glucose was associated with all-cause mortality, even when accounting for standard measures of glucose control as well as comorbidity and lifestyle factors.

Entities:  

Keywords:  Mortality; glycaemic control; hypoglycaemia; long-term glycaemic variability; type 2 diabetes

Mesh:

Substances:

Year:  2019        PMID: 31014099      PMCID: PMC7380497          DOI: 10.1177/1479164119827598

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  35 in total

1.  Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications.

Authors:  Michael Brownlee; Irl B Hirsch
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

2.  Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes.

Authors:  S L Wang; J Head; L Stevens; J H Fuller
Journal:  Diabetes Care       Date:  1996-04       Impact factor: 19.112

3.  Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.

Authors:  Rodney A Hayward; Peter D Reaven; Wyndy L Wiitala; Gideon D Bahn; Domenic J Reda; Ling Ge; Madeline McCarren; William C Duckworth; Nicholas V Emanuele
Journal:  N Engl J Med       Date:  2015-06-04       Impact factor: 91.245

Review 4.  Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.

Authors:  Christoph Stettler; Sabin Allemann; Peter Jüni; Carole A Cull; Rury R Holman; Matthias Egger; Stephan Krähenbühl; Peter Diem
Journal:  Am Heart J       Date:  2006-07       Impact factor: 4.749

5.  Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.

Authors:  Craig J Currie; John R Peters; Aodán Tynan; Marc Evans; Robert J Heine; Oswaldo L Bracco; Tony Zagar; Chris D Poole
Journal:  Lancet       Date:  2010-01-26       Impact factor: 79.321

Review 6.  Glucose Variability: A Review of Clinical Applications and Research Developments.

Authors:  David Rodbard
Journal:  Diabetes Technol Ther       Date:  2018-06       Impact factor: 6.118

7.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

Authors:  Louis Monnier; Emilie Mas; Christine Ginet; Françoise Michel; Laetitia Villon; Jean-Paul Cristol; Claude Colette
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

8.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial.

Authors:  Jin J Zhou; Dawn C Schwenke; Gideon Bahn; Peter Reaven
Journal:  Diabetes Care       Date:  2018-08-06       Impact factor: 19.112

View more
  8 in total

Review 1.  Review of the veteran affairs diabetes trial: Lessons learned.

Authors:  Kelvin Tran; Peter Reaven
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 2.  New Insights into the Role of Visit-to-Visit Glycemic Variability and Blood Pressure Variability in Cardiovascular Disease Risk.

Authors:  Jin J Zhou; Daniel S Nuyujukian; Peter D Reaven
Journal:  Curr Cardiol Rep       Date:  2021-03-02       Impact factor: 2.931

Review 3.  Endothelial Dysfunction and Platelet Hyperactivation in Diabetic Complications Induced by Glycemic Variability.

Authors:  Ye Huang; Long Yue; Jiahuang Qiu; Ming Gao; Sijin Liu; Jingshang Wang
Journal:  Horm Metab Res       Date:  2022-07-14       Impact factor: 2.788

Review 4.  Diabetes and Cardiovascular Disease: an Update.

Authors:  Rajaa Almourani; Bhavana Chinnakotla; Richa Patel; L Romayne Kurukulasuriya; James Sowers
Journal:  Curr Diab Rep       Date:  2019-12-11       Impact factor: 4.810

5.  Predictors of mortality among patients with type 2 diabetes in Jordan.

Authors:  Fadia Abdallah Mayyas; Khalid Shaker Ibrahim
Journal:  BMC Endocr Disord       Date:  2021-10-12       Impact factor: 2.763

6.  Refining determinants of associations of visit-to-visit blood pressure variability with cardiovascular risk: results from the Action to Control Cardiovascular Risk in Diabetes Trial.

Authors:  Daniel S Nuyujukian; Jin J Zhou; Juraj Koska; Peter D Reaven
Journal:  J Hypertens       Date:  2021-11-01       Impact factor: 4.844

7.  Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT.

Authors:  Jin J Zhou; Juraj Koska; Gideon Bahn; Peter Reaven
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

8.  Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT).

Authors:  Juraj Koska; Daniel S Nuyujukian; Gideon D Bahn; Jin J Zhou; Peter D Reaven
Journal:  Cardiovasc Diabetol       Date:  2021-12-08       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.